SCHEMBL1737797

SCHEMBL1737797

CC(=O)Oc1ccc(Br)cc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 2/20 0.53
ALDH1A1 P00352 6/20 0.47
HPGD P15428 2/20 0.47
POLB P06746 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ACHE P22303 1/20 0.46
KDM4E B2RXH2 4/20 0.46
RAB9A P51151 2/20 0.46
TSHR P16473 2/20 0.46
GAA P10253 1/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTT P42858 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
PTGS1 P23219 2/20 0.43
PTGS2 P35354 2/20 0.43
ESR1 P03372 1/20 0.43
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8895553 0.85 ACHE (0.59) CFDALDH1A1HPGDPOLBACHE
SCHEMBL3453790 0.84 TSHR (0.58) CFDALDH1A1HPGDKDM4ERAB9A
SCHEMBL4314746 0.82 CFD (0.55) CFDALDH1A1HPGDKDM4ERAB9A
SCHEMBL2569698 0.81 ALDH1A1 (0.48) ALDH1A1HPGDPOLBNPSR1KDM4E
SCHEMBL789388 0.81 PTGDR2 (0.63) CFDALDH1A1HPGDPOLBKDM4E
SCHEMBL25027 0.81 CFD (0.73) CFDALDH1A1HPGDPOLBKDM4E
SCHEMBL16397172 0.81 CFD (0.53) CFDALDH1A1HPGDKDM4ERAB9A
SCHEMBL5929563 0.80 ACHE (0.50) ALDH1A1HPGDPOLBNPSR1ACHE
SCHEMBL20660752 0.80 ALDH1A1 (0.47) ALDH1A1HPGDPOLBNPSR1ACHE
SCHEMBL6992953 0.80 KDM4E (0.44) ALDH1A1HPGDPOLBNPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4734976-A2 AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS RyCarma Therapeutics, Inc. (US) 2026-05-06 EP disclosed
US-20250382312-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF BORAH INC (US) 2025-12-18 US disclosed
US-12404286-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof BORAH, INC. (US) 2025-09-02 US disclosed
WO-2025006617-A2 AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS ARMGO PHARMA, INC. (US) 2025-01-02 WO disclosed
US-20240352045-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2024-10-24 US disclosed
CN-117242080-A Boron-containing pyrazole compounds, compositions comprising the same, methods and uses thereof 勃林格殷格翰动物保健美国公司 2023-12-15 CN disclosed
US-11827657-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof Boehringer Ingelheim Animal Health USA Inc. (US) 2023-11-28 US disclosed
US-11827657-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof Boehringer Ingelheim Animal Health USA Inc. (US) 2023-11-28 US disclosed
US-11827657-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof Boehringer Ingelheim Animal Health USA Inc. (US) 2023-11-28 US disclosed
EP-4263559-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF Boehringer Ingelheim Animal Health USA Inc. (US) 2023-10-25 EP disclosed
US-7479559-B2 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation PFIZER INC. (US) 2009-01-20 US disclosed
EP-1727794-A1 NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES Pfizer Products Incorporated (US) 2006-12-06 EP disclosed
EP-1673088-A1 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-06-28 EP disclosed
WO-2006048727-A1 PIPERAZINYLPHENALKYL LACTAM/AMINE LIGANDS FOR THE 5HT1B RECEPTOR PFIZER PRODUCTS INC. (US) 2006-05-11 WO disclosed
US-20050245521-A1 Novel benayl(idene)-lactam derivatives PFIZER INC. 2005-11-03 US disclosed
WO-2005090300-A1 NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES PFIZER PRODUCTS INC. (US) 2005-09-29 WO disclosed
US-20050176706-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-11 US disclosed
WO-2005030213-A1 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-04-07 WO disclosed
WO-2005010202-A2 PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS LIGAND PHARMACUETICALS INCORPORATED (US) 2005-02-03 WO disclosed
US-20040235916-A1 Thiazolyl amides and their use as antiviral drugs SCHOHE-LOOP RUDOLF (DE) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827657-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof JAK3, JAK1, JAK2 CFD 3734/4885ALDH1A1 3977/4885HPGD 3338/4885
US-20050176706-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof NR3C1, NR3C2, MC2R CFD 759/4885ALDH1A1 3621/4885HPGD 1302/4885
US-20250382312-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF JAK3, JAK1, JAK2 CFD 3734/4885ALDH1A1 3977/4885HPGD 3338/4885
US-20040235916-A1 Thiazolyl amides and their use as antiviral drugs EIF2AK2, MAVS, ZC3HAV1 CFD 3463/4885ALDH1A1 952/4885HPGD 3025/4885
US-20240352045-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF JAK3, JAK1, JAK2 CFD 3734/4885ALDH1A1 3977/4885HPGD 3338/4885
US-20050245521-A1 Novel benayl(idene)-lactam derivatives HTR1E, HTR1D, HTR1A CFD 3137/4885ALDH1A1 411/4885HPGD 3306/4885
US-12404286-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof JAK3, JAK1, JAK2 CFD 3734/4885ALDH1A1 3977/4885HPGD 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.